NAMS

+ Watchlist + Portfolio

NewAmsterdam Pharma Company N.V.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $23.20
52-Week Range: $21.02 – $42.21
Market Cap: $2.74B
P/E (TTM): —
EPS (TTM): -2.16
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 4.26
PEG Ratio: —
Return on Equity: -36.81%
Return on Assets: -20.11%
Gross Margin: 100.00%
Operating Margin: -1752.61%
Profit Margin: 0.00%
Current Ratio: 9.03
Debt/Equity: 0.00
Total Debt: $82.00K
Free Cash Flow: $-45.36M
Revenue Growth: -80.70%
Earnings Growth: —
Enterprise Value: $2.14B

NAMS Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$102.69M	$14.09M	$45.56M	$22.50M
Research & Development	$86.74M	$159.42M	$151.41M	$141.83M
Selling, General & Admin	$19.51M	$37.63M	$70.45M	$106.35M
Operating Expenses	$106.25M	$197.06M	$221.85M	$248.19M
Operating Income	-$3.56M	-$182.97M	-$176.29M	-$225.68M
EBITDA	-$22.34M	-$182.92M	-$176.18M	-$225.46M
Pretax Income	-$22.63M	-$176.91M	-$241.60M	-$203.82M
Income Tax	$0.00	$27.00K	-$1.00K	$0.00
Net Income	-$22.63M	-$176.94M	-$241.60M	-$203.82M
Diluted EPS	-1.19	-2.15	-2.56	-1.78
Diluted Shares	18.97M	82.16M	94.36M	114.40M

NAMS Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$467.73M	$340.45M	$771.74M	$490.00M
Receivables	$2.07M	$1.88M	$21.30M	$23.15M
Current Assets	$477.98M	$346.79M	$863.41M	$675.70M
Total Assets	$478.50M	$347.10M	$864.62M	$769.28M
Current Liabilities	$36.06M	$49.90M	$106.92M	$85.79M
Total Debt	$126.00K	$60.00K	$448.00K	$202.00K
Total Liabilities	$48.43M	$58.70M	$107.12M	$85.85M
Retained Earnings	-$140.04M	-$316.97M	-$558.57M	-$762.39M
Shareholders' Equity	$430.07M	$288.39M	$757.50M	$683.43M
Working Capital	$441.92M	$296.89M	$756.50M	$589.91M

NAMS Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$10.66M	-$141.22M	-$158.56M	-$147.78M
Capital Expenditure	-$221.00K	-$24.00K	-$672.00K	-$246.00K
Free Cash Flow	$10.44M	-$141.24M	-$159.24M	-$148.03M
Depreciation & Amortisation	$9.00K	$49.00K	$113.00K	$220.00K
Stock-Based Compensation	$4.12M	$24.57M	$33.62M	$59.42M
Investing Cash Flow	-$221.00K	-$24.00K	-$62.85M	-$174.92M
Financing Cash Flow	$391.90M	$8.91M	$659.51M	$29.52M
Net Change in Cash	$402.35M	-$132.33M	$438.10M	-$293.18M

NAMS Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$2.98M	$19.14M	$348.00K	$32.00K	$3.04M	$3.70M
Research & Development	$44.75M	$27.52M	$30.97M	$38.59M	$38.01M	$41.67M
Selling, General & Admin	$27.15M	$27.26M	$24.52M	$27.42M	$23.45M	$26.89M
Operating Expenses	$71.90M	$54.78M	$55.49M	$66.01M	$61.46M	$68.56M
Operating Income	-$68.92M	-$35.63M	-$55.14M	-$65.98M	-$58.42M	-$64.86M
EBITDA	-$68.87M	-$35.59M	-$55.08M	-$65.92M	-$58.36M	-$64.81M
Pretax Income	-$39.53M	-$17.36M	-$72.00M	-$74.92M	-$48.44M	-$64.14M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$39.53M	-$17.36M	-$72.00M	-$74.92M	-$48.44M	-$64.14M
Diluted EPS	-0.34	-0.15	-0.61	—	-0.40	-0.55
Diluted Shares	116.12M	112.51M	119.00M	—	121.72M	117.65M

NAMS Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$748.42M	$563.86M	$538.41M	$490.00M	$457.61M	$424.15M
Receivables	$1.61M	$19.75M	$20.25M	$23.15M	$8.22M	$5.34M
Current Assets	$817.30M	$769.85M	$732.33M	$675.70M	$658.04M	$659.21M
Total Assets	$818.41M	$815.11M	$786.43M	$769.28M	$732.64M	$704.45M
Current Liabilities	$40.91M	$36.51M	$58.27M	$85.79M	$67.42M	$72.97M
Total Debt	$389.00K	$328.00K	$266.00K	$202.00K	$23.00K	$82.00K
Total Liabilities	$41.05M	$36.62M	$58.36M	$85.85M	$67.42M	$73.03M
Retained Earnings	-$598.10M	-$615.46M	-$687.47M	-$762.39M	-$810.83M	-$874.97M
Shareholders' Equity	$777.36M	$778.50M	$728.07M	$683.43M	$665.22M	$631.42M
Working Capital	$776.39M	$733.34M	$674.06M	$589.91M	$590.62M	$586.23M

NAMS Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$36.47M	-$37.67M	-$32.77M	-$40.88M	-$30.60M	-$39.21M
Capital Expenditure	-$16.00K	-$88.00K	-$42.00K	-$100.00K	-$38.00K	-$80.00K
Free Cash Flow	-$36.48M	-$37.76M	-$32.81M	-$40.98M	-$30.64M	-$39.29M
Depreciation & Amortisation	$52.00K	$45.00K	$64.00K	$59.00K	$62.00K	$59.00K
Stock-Based Compensation	$15.21M	$15.18M	$15.01M	$14.02M	$18.00M	$18.38M
Investing Cash Flow	$2.85M	-$159.14M	$2.51M	-$21.14M	-$11.51M	-$4.76M
Financing Cash Flow	$6.52M	$3.42M	$5.89M	$13.68M	$11.06M	$11.04M
Net Change in Cash	-$27.09M	-$193.38M	-$24.37M	-$48.33M	-$31.05M	-$32.94M

Market Snapshot

About

NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company developing oral therapies for cardiovascular disease. The company focuses on lipid-lowering treatments targeting patients with high cholesterol who remain at risk despite current therapies.